Press release
Plaque Psoriasis in 68 Market is Expected to Reach USD 26.9 Billion by 2034
Plaque Psoriasis in 68
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73643
Recent years have witnessed an unprecedented evolution in psoriasis treatment. The market has moved beyond traditional topical and phototherapy treatments toward advanced biologics and small molecule inhibitors, offering long-term disease control and improved quality of life. Fueled by the growing adoption of interleukin-targeted therapies, biosimilars, and digital dermatology platforms, the plaque psoriasis market is entering a high-growth phase that will redefine chronic skin disease management through 2034.
Market Overview
• Market Size (2024): USD 11.3 billion (estimated)
• Forecast (2034): USD 26.9 billion
• CAGR (2024-2034): ~8.9%
Key Growth Drivers:
• Rising global prevalence of psoriasis, especially plaque-type cases.
• Increasing use of biologics (IL-17, IL-23, and TNF inhibitors).
• Technological innovations in patient management and teledermatology.
• Expanding access to biosimilars, making advanced therapy more affordable.
Challenges:
• High cost of biologic and small-molecule treatments.
• Unequal access to dermatologic care in developing nations.
• Long-term disease management and recurrence issues.
Leading Companies:
AbbVie Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., Johnson & Johnson, Bristol Myers Squibb, UCB Pharma, Pfizer Inc., Leo Pharma A/S, Sun Pharmaceutical Industries Ltd.
Segmentation Analysis
By Treatment Type
• Biologics (IL-17 Inhibitors, IL-23 Inhibitors, IL-12/23 Inhibitors, TNF Inhibitors)
• Small Molecule Therapies (PDE4 Inhibitors, JAK Inhibitors)
• Topical Agents (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Phototherapy
• Others (Combination Therapies, Emerging Modalities)
By Route of Administration
• Injectable
• Oral
• Topical
By Severity Level
• Mild
• Moderate
• Severe
By End User
• Hospitals & Dermatology Clinics
• Specialty Pharmacies
• Homecare Settings
• Research & Academic Institutes
Summary:
Biologics dominate the global market, accounting for the highest revenue share due to superior efficacy and long-term disease control. IL-17 and IL-23 inhibitors are the fastest-growing classes, offering targeted treatment with improved safety. Meanwhile, small molecule drugs like PDE4 and JAK inhibitors are emerging as convenient oral options. Topical agents continue to play an essential role for mild to moderate cases.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market
Regional Analysis
North America
• Largest market in 2024 due to widespread availability of biologics, strong insurance coverage, and rapid adoption of new therapies.
• The U.S. leads with approvals of Skyrizi (AbbVie), Cosentyx (Novartis), and Taltz (Eli Lilly).
Europe
• Strong clinical adoption in Germany, France, and the UK supported by national healthcare systems.
• EMA approvals driving biosimilar competition and cost-effective access.
Asia-Pacific
• Fastest-growing region (CAGR ~10.4%) due to increasing prevalence, growing awareness, and local biosimilar production.
• China, India, and Japan emerging as key growth markets.
Middle East & Africa
• Growing market share in GCC nations with expanding dermatology clinics and higher disposable incomes.
• Limited access in rural regions and underdeveloped healthcare systems.
Latin America
• Moderate growth driven by expanding dermatological infrastructure and public health initiatives in Brazil and Mexico.
Summary:
While North America and Europe currently dominate the market, Asia-Pacific is poised to become the fastest-growing region, driven by biosimilar expansion, improved diagnosis, and government-led healthcare reforms.
Market Dynamics
Key Growth Drivers
• Expansion of biologic pipelines with next-generation IL inhibitors.
• Increasing demand for personalized and precision dermatology.
• Rising use of digital platforms for remote monitoring and teleconsultation.
• Growing patient awareness and social acceptance of chronic skin conditions.
Key Challenges
• Cost-related barriers and reimbursement limitations for biologic therapies.
• Long-term adherence challenges and disease recurrence.
• Limited dermatologist availability in emerging economies.
Latest Trends
• Surge in biosimilar approvals improving treatment affordability.
• Integration of AI in dermatology diagnostics and treatment monitoring.
• Development of oral small molecules (deucravacitinib, apremilast) for easier administration.
• Focus on patient-centered care with mobile apps and wearable adherence tracking.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73643
Competitor Analysis
Major Players:
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• UCB Pharma
• Pfizer Inc.
• Leo Pharma A/S
• Sun Pharmaceutical Industries Ltd.
Competitive Landscape:
The plaque psoriasis market is highly competitive and innovation-driven. AbbVie's Skyrizi (IL-23 inhibitor) and Eli Lilly's Taltz (IL-17A inhibitor) lead the field in market adoption and patient outcomes. Novartis' Cosentyx remains a blockbuster biologic, while Pfizer and Bristol Myers Squibb are investing in oral therapies such as deucravacitinib, targeting moderate cases. The introduction of biosimilars and next-generation IL-17F inhibitors is intensifying competition and improving affordability across regions.
Conclusion
The Plaque Psoriasis Market (In-68) is projected to grow from USD 11.3 billion in 2024 to USD 26.9 billion by 2034, at a CAGR of 8.9%. Fueled by breakthroughs in biologics, the emergence of small molecule inhibitors, and increasing accessibility of biosimilars, the market outlook remains robust and transformative.
Despite high treatment costs and adherence challenges, innovations in AI-assisted dermatology, digital adherence monitoring, and personalized immunotherapy are reshaping care standards. Asia-Pacific's growing influence and biosimilar production capabilities are further expanding global reach.
Key Takeaway: Companies that integrate next-generation IL-targeted biologics, digital patient engagement tools, and precision dermatology platforms will lead the next decade of plaque psoriasis care, bridging efficacy with affordability.
This report is also available in the following languages : Japanese (68人の尋常性乾癬), Korean (68세의 플라크 건선), Chinese (68 例斑块状银屑病), French (Psoriasis en plaques chez 68), German (Plaque-Psoriasis bei 68), and Italian (Psoriasi a placche nel 68), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market#request-a-sample
Our More Reports:
Digital Thermo Anemometer Market
https://exactitudeconsultancy.com/reports/75213/digital-thermo-anemometer-market
Multi-Screen Super Glass Market
https://exactitudeconsultancy.com/reports/75214/multi-screen-super-glass-market
Mining Pneumatic Saw Market
https://exactitudeconsultancy.com/reports/75215/mining-pneumatic-saw-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis in 68 Market is Expected to Reach USD 26.9 Billion by 2034 here
News-ID: 4209806 • Views: …
More Releases from Exactitude Consultancy
Alzheimer's Disease in 68 Market Projected to Reach USD 15.7 Billion by 2034
Alzheimer's disease (AD) - a progressive neurodegenerative disorder characterized by memory loss, cognitive impairment, and behavioral decline - remains one of the most pressing global healthcare challenges. Accounting for nearly 60-70% of dementia cases, Alzheimer's affects over 55 million people worldwide, a figure expected to triple by 2050 as populations age.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73641
Despite decades of research, the disease's complexity has hindered curative treatment…
Industrial Biofuel Processing Machinery Market USD 7.8B in 2024, Expected to Rea …
Introduction
With growing global urgency to transition toward cleaner energy, biofuels have emerged as a vital component of the renewable energy mix. Industrial biofuel processing machinery plays a crucial role in converting organic feedstocks-such as agricultural residues, vegetable oils, animal fats, and algae-into bioethanol, biodiesel, and advanced biofuels. These machines encompass reactors, fermenters, distillation columns, centrifuges, and filtration units that enable large-scale, efficient, and sustainable fuel production.
According to Exactitude Consultancy, the…
Wafer Batch Aligner Market USD 405M in 2024, Expected to Reach USD 715M by 2034 …
Introduction
With the growing demand for advanced microelectronics, wafer batch aligners have become indispensable in semiconductor fabrication. These precision systems enable the accurate alignment of silicon wafers during photolithography and packaging processes-an essential step for ensuring chip quality, yield, and performance. The integration of wafer batch aligners in modern fabrication lines supports high-throughput operations and sub-micron alignment accuracy, which are vital for the production of logic ICs, memory devices, MEMS, sensors,…
Parkinson's Disease in 68 Market Projected to Reach USD 13.2 Billion by 2034
Parkinson's disease (PD) is the second most common neurodegenerative disorder globally, characterized by the progressive loss of dopamine-producing neurons in the brain. The condition leads to motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor complications like depression, cognitive impairment, and sleep disturbances.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73647
With over 10 million people worldwide affected and prevalence rising with an aging population, Parkinson's disease…
More Releases for Psoriasi
Psoriasis Patient Pool Analysis Market Forecast to Reach USD 32.5 Billion by 203 …
Psoriasis is a chronic, immune-mediated skin condition characterized by red, scaly plaques that significantly affect patients' physical and emotional well-being. Beyond the skin, psoriasis is linked to systemic comorbidities such as psoriatic arthritis, cardiovascular disease, and depression. With millions affected globally, psoriasis remains a major public health issue.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71525
The psoriasis patient pool is steadily expanding due to rising diagnosis rates, better awareness…
Generalized Pustular Psoriasis (GPP) Market is expected to reach USD 3.1 billion …
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread sterile pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP can cause acute episodes that require emergency care, making it a critical unmet need in dermatology.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71539
Until recently, treatment options for GPP were limited to off-label use of systemic therapies and immunosuppressants. However, the…
Phototherapies for Psoriasis Market Set to Witness Significant Growth by 2025-20 …
Introduction
Psoriasis is a chronic autoimmune skin condition characterized by rapid skin cell turnover, leading to scaling, inflammation, and plaques. Affecting millions globally, psoriasis is not only a dermatological concern but also a systemic disorder linked to comorbidities such as arthritis, cardiovascular disease, and metabolic syndrome.
Phototherapy has long been an established treatment option for moderate-to-severe psoriasis, leveraging controlled ultraviolet (UV) light to slow skin cell growth and reduce inflammation. Recent advancements…
Chronic Plaque Psoriasis Market is expected to double, reaching USD 36 billion b …
Chronic plaque psoriasis is the most common form of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune disease characterized by raised, inflamed, and scaly skin patches that significantly affect patients' quality of life. While topical therapies and phototherapy have long been standard treatments, the advent of biologics and targeted small molecules has transformed the market.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71377
With…
Generalized Pustular Psoriasis (GPP) Market Emerging Trends and Growth Prospects …
Introduction
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP is less common but often far more severe, requiring urgent treatment and long-term disease management.
With increasing awareness, advances in biologics, and the emergence of targeted therapies specifically developed for GPP, the global market is entering a transformative phase. Over the next decade, pharmaceutical…
Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Oppo …
Introduction
Psoriasis is a chronic, immune-mediated skin disorder marked by red, scaly plaques that can cause significant physical discomfort and psychological burden. Among the different types, moderate to severe psoriasis requires systemic therapy or biologics due to its extensive nature and comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71343
Historically, management involved topical corticosteroids, phototherapy, and systemic drugs like methotrexate or…
